Nuformix Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Nuformix CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Gooding	Executive Director	2.3yrs	UK£30.00k	4.58% € 24.3k
Julian Gilbert	Senior Independent Non-Executive Chairman	4yrs	UK£51.00k	0.031% € 162.2
Alan Chorlton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Chris Frampton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Andy Richards	Chairman of Advisory Panel	6.9yrs	Veri yok	Veri yok
Derek Mann	Member of Advisory Panel	5.9yrs	Veri yok	Veri yok
Jeffery Lindeman	Member of Advisory Board	no data	Veri yok	Veri yok
Madeleine Kennedy	Independent Non-Executive Director	3.9yrs	UK£51.00k	0.031% € 162.2

4.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1RT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Nuformix Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Nuformix plc, Annual General Meeting, Mar 19, 2024

Nuformix plc, Annual General Meeting, Aug 24, 2023

Nuformix plc, Annual General Meeting, Aug 25, 2022

Nuformix plc Announces Board Changes, Effective August 1, 2022

Nuformix plc Announces Directorate Change

Nuformix plc Announces Resignation of Chris Blackwell as Non-Executive Chairman and Director

Recent updates

New major risk - Financial position

Nuformix plc has completed a Follow-on Equity Offering in the amount of £0.15 million.

Nuformix plc has filed a Follow-on Equity Offering in the amount of £0.15 million.

Nuformix plc has filed a Follow-on Equity Offering in the amount of £0.15 million.

New minor risk - Financial data availability

Nuformix plc, Annual General Meeting, Mar 19, 2024

New minor risk - Financial data availability

Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan

Nuformix plc, Annual General Meeting, Aug 24, 2023

Nuformix plc Announces Update Regarding the NXP002 Programme

Nuformix plc Announces NXP004 Update

Nuformix plc Announces Update Regarding the Company's NXP002 Programme, A Proprietary New Form of Tranilast, Being Developed as A Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis

Nuformix plc Announces NXP002 Completion of Tolerability Studies

Nuformix plc, Annual General Meeting, Aug 25, 2022

Full year 2022 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in FY 2021)

Nuformix plc Announces Board Changes, Effective August 1, 2022

Nuformix plc Provides NXP004 Update

Nuformix plc Provides NXP002 Update

Nuformix plc Announces Directorate Change

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Nuformix plc Provides an Update on Its Lead Asset, NXP002

Full year 2021 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in FY 2020)

Nuformix plc Announces Notice of Allowance of Patent in US

Nuformix plc Provides Project Update - Progress on NXP002 and NXP004

Senior Independent Director has left the company

Chief Scientific Officer & Director has left the company

Non-Executive Chairman Christopher Blackwell has left the company

Nuformix plc Announces Resignation of Chris Blackwell as Non-Executive Chairman and Director

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş